Finally, Morgan Stanley reduced their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. 10 Stocks to Sell NOW!

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...

Deutsche Bank Aktiengesellschaft started coverage on shares of Biohaven in a research report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price objective on the stock.

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd.

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN ... its model and says it expects the primary focus for the stock to remain on upcoming FDA action on Troriluzole for ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the announcement as ...

We assign a $60 price target through 2025 and despite the cash cliff the company is facing, we believe under $40 Biohaven is a strong buy. Analyst’s Disclosure: I/we have no stock, option or ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...

Officers, 10% owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the ...